Curcumin possesses many properties which may prevent or ameliorate pathological processes underlying age-related cognitive decline, dementia or mood disorders. However, these benefits in preclinical studies have not been established in humans.

This randomized, double-blind, placebo-controlled trial examined the acute (one and three hours after a single dose), chronic (four weeks) and acute-on-chronic (one and three hour after single dose following chronic treatment) effects of solid lipid curcumin formulation (400 mg as Longvida®) on cognitive function, mood and blood biomarkers in 60 healthy adults aged 60 to 85 years.

READ FULL ARTICLE Curated publisher From jop.sagepub.com